2023 World Conference on Lung Cancer (Posters)-P2.09. Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated

P2.09. Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated - PDF(Abstract)

Back to course

Pdf Summary

This abstract presents the findings of a study on the safety and efficacy of aumolertinib, a targeted therapy, in patients with advanced non-small cell lung cancer (NSCLC) who have uncommon epidermal growth factor receptor (EGFR) mutations. The study included 20 patients with locally advanced or metastatic NSCLC and focused on cohort 2 of the trial. The primary endpoint was the safety of aumolertinib, and secondary endpoints included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).<br /><br />The results showed that aumolertinib demonstrated a tolerable safety profile and encouraging antitumor activity in patients with advanced NSCLC harboring uncommon EGFR mutations. Of the 17 patients included in the efficacy analysis, the overall ORR was 47.1%, the DCR was 100%, and the median PFS was 11.8 months. Subgroup analysis based on different genotypes of EGFR mutations revealed varying response rates, with ORR ranging from 33.3% to 50%.<br /><br />No new safety signals or concerns were identified in the study. The authors conclude that high-dose aumolertinib may be an effective treatment option for patients with advanced NSCLC who have uncommon EGFR mutations. The study also mentions that high-dose aumolertinib is currently being evaluated in a phase 3 clinical trial for patients with uncommon EGFR mutations.<br /><br />In summary, this study suggests that high-dose aumolertinib shows promise in treating advanced NSCLC with uncommon EGFR mutations, demonstrating favorable safety and antitumor activity. Further research through phase 3 clinical trials is ongoing to confirm these findings.

Asset Subtitle

Wen Fang

Meta Tag

Speaker Wen Fang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

aumolertinib

targeted therapy

NSCLC

EGFR mutations

safety

efficacy

antitumor activity

phase 3 clinical trial

advanced NSCLC

research